Join the Eczema group to help and get support from people like you.
Eczema News (Page 2)
Dupilumab Efficacious for Atopic Dermatitis in Young Children
WEDNESDAY, Dec. 11, 2024 – Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published in the December issue of Advances in Therapy. ...
Breathing Dirty Air Might Raise Eczema Risks
FRIDAY, Nov. 15, 2024 – Cases of the autoimmune skin condition eczema appear to rise in areas most plagued by air pollution, new research shows. Since data has long shown that rates of eczema --...
Greater Fine Particulate Matter Linked to Increased Odds of Eczema
WEDNESDAY, Nov. 13, 2024 – The odds of eczema are increased with greater exposure to fine particulate matter of diameter ≤2.5 μm (PM2.5), according to a study published online Nov. 13 in PLOS ONE. Gl...
FDA Medwatch Alert: Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health
October 30, 2024 – FDA is warning consumers to not purchase or use Skin-Cap aerosol spray products because they may contain undisclosed steroids. This product, sold by Chemigroup France, formerly...
Are 'Elimination Diets' Much Help Against Child Eczema?
FRIDAY, Oct. 25, 2024 – Cutting certain foods from a child’s diet isn’t likely to improve their eczema symptoms, a new study finds. Eczema, also known as atopic dermatitis, results from an ove...
Eczema Could Be Linked to Poorer Leg Artery Function
TUESDAY, Oct. 22, 2024 – The skin condition eczema appears to be linked to a serious condition that can end in leg amputation, a new study finds. People with eczema are at significantly higher risk...
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema
FRIDAY, Oct. 4, 2024 – For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has long-term efficacy, according to a study presented at the annual meeting of the European Academy...
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Sept. 18, 2024 – The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis....
Link Between n-3 LCPUFA, Eczema Varies by Maternal COX1 Genotype
WEDNESDAY, Sept. 4, 2024 – The association of prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) with the risk for childhood atopic dermatitis (AD) varies based on the maternal ...
Dietary Vitamin E May Be Protective Against Atopic Dermatitis
FRIDAY, Aug. 30, 2024 – Dietary intake of vitamin E may potentially lower the risk for atopic dermatitis, according to a study published online Aug. 9 in Skin Research & Technology. Siqing Wang, ...
Obese Kids May Face Higher Odds for Eczema, Psoriasis
WEDNESDAY, Aug. 21, 2024 – Obese kids are more likely to develop immune-based skin problems like eczema or psoriasis, a new study says. Analysis of more than 2.1 million Korean children between 2009...
Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
MONDAY, Aug. 12, 2024 – For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8 percent of patients, according to a...
Gen Z Perceives Atopic Dermatitis to Be More Severe
TUESDAY, July 30, 2024 – Generation Z (Gen Z) patients present with a higher subjective perception of atopic dermatitis severity than millennial generation patients, according to a study published...
Atopic Dermatitis Has Large Impact on Sexual Function Among Women
MONDAY, July 29, 2024 – Most women with atopic dermatitis have impairment in sexual function, and about half consider that atopic dermatitis may influence their reproductive desire, according to a...
Atopic Dermatitis Has Large Impact on Sexual Function Among Women
MONDAY, July 29, 2024 – Most women with atopic dermatitis have impairment in sexual function, and about half consider that atopic dermatitis may influence their reproductive desire, according to a...
Further information
Related condition support groups
Related drug support groups
prednisone, methotrexate, clobetasol, Dupixent, fluocinonide, dexamethasone, desonide, dupilumab, halobetasol